Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vaxcyte, Inc.

37.09
+0.10000.27%
Volume:894.39K
Turnover:33.06M
Market Cap:4.78B
PE:-9.32
High:38.39
Open:37.91
Low:36.26
Close:36.99
Loading ...

Small U.S. Stocks End Mixed As CoreWeave Cl A Lead, Vaxcyte Lags

Dow Jones
·
02 Apr

BUZZ-Vaxcyte down after Leerink's PT cut

Reuters
·
01 Apr

Vaxcyte Inc : Bofa Global Research Cuts Price Objective to $137 From $157

THOMSON REUTERS
·
01 Apr

Vaxcyte Is Maintained at Buy by Needham

Dow Jones
·
01 Apr

Vaxcyte price target lowered to $90 from $140 at Needham

TIPRANKS
·
01 Apr

Needham Cuts Price Target on Vaxcyte to $90 From $140, Maintains Buy Rating

MT Newswires Live
·
01 Apr

Vaxcyte’s VAX-24: Promising Infant Vaccine Results Amidst Investor Concerns

TIPRANKS
·
01 Apr

Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials

TIPRANKS
·
01 Apr

Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI

TIPRANKS
·
01 Apr

BUZZ-Vaxcyte falls as pneumococcal vaccine data fails to meet lofty investor expectations

Reuters
·
01 Apr

Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet

Benzinga
·
31 Mar

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

Dow Jones
·
31 Mar

Vaxcyte Shares Drop 56% to Lowest Since October 2022 After Results From Vax-24 Infant Phase 2 Dose-Finding Study

THOMSON REUTERS
·
31 Mar

Vaxcyte VAX-24 Vaccine Data Missed Wall Street Expectations, But Fundamentally Still Positive, Mizuho Securities Says

MT Newswires Live
·
31 Mar

Wall Street Set to Open Lower Monday as Investors Gird for More Tariffs, Await Key Manufacturing Data

MT Newswires Live
·
31 Mar

Top Premarket Decliners

MT Newswires Live
·
31 Mar

Vaxcyte's Pneumococcal Conjugate Vaccine Candidate Shows Substantial Immune Response in Infants

MT Newswires Live
·
31 Mar

Investors Brace for 'Liberation Day' as US Futures Trend Sharply Lower in Monday's Premarket

MT Newswires Live
·
31 Mar

S&P 500 Futures Fall In Premarket Trading; Vaxcyte, Moderna Lag

Dow Jones
·
31 Mar

Vaxcyte reports topline results from VAX-24 infant Phase 2 dose-finding study

TIPRANKS
·
31 Mar